Impact of Cardiovascular Comorbidity on Ovarian Cancer Mortality

Shinn, Eileen H.; Lenihan, Daniel J.; Urbauer, Diana L.; Basen-Engquist, Karen; Valentine, Alan D.; Palmero, Laura C.; Woods, Myrshia; Patel, Pooja; Nick, Alpa M.; Shahzad, Mian M.K.; Stone, Rebecca L.; Golden, Antoinette; Atkinson, E. Neely; Lutgendorf, Susan K.; Sood, Anil K.

doi:10.1158/1055-9965.epi-13-0625

Cited by 19 publications

(21 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Prior research on the impact of comorbidities on stage at diagnosis has yielded inconsistent findings, but our results align with much of the ovarian cancer-specific research. [36][37][38][39] Prior research has found that having multiple comorbidities is associated with advanced stage at diagnosis and less aggressive treatment courses for ovarian cancer; both have been shown to increase the risk of death from ovarian cancer by 40%. [36][37][38][39] Our nonsignificant findings also align with the theory of competing demand, which postulates comorbidities distract patients and physicians from noticing tumor growth and cancer symptoms.…”

Section: Discussionmentioning

confidence: 99%

Impact of Rurality on Stage IV Ovarian Cancer at Diagnosis: A Midwest Cancer Registry Cohort Study

Weeks

Lynch

West

et al. 2020

The Journal of Rural Health

View full text Add to dashboard Cite

Purpose We aim to understand if rurality impacts patients’ odds of presenting with stage IV ovarian cancer at diagnosis independent of distance to primary care provider and the socioeconomic status of a patient's residential census tract. Methods A cohort of 1,000 women with ovarian cancer in Iowa, Kansas, and Missouri were sampled and analyzed from the cancer registries’ statewide population data. The sample contained those with a histologically confirmed primary ovarian cancer diagnosis in 2011‐2012. All variables were captured through an extension of standard registry protocol using standardized definitions and abstraction manuals. Chi‐square tests and a multivariable logistic regression model were used. Findings At diagnosis, 111 women in our sample had stage IV cancer and 889 had stage I‐III. Compared to patients with stage I‐III cancer, patients with stage IV disease had a higher average age, more comorbidities, and were more often living in rural areas. Multivariate analysis showed that rural women (vs metropolitan) had a greater odds of having stage IV ovarian cancer at diagnosis (odds ratio = 2.41 and 95% confidence interval = 1.33‐4.39). Conclusion Rural ovarian cancer patients have greater odds of having stage IV cancer at diagnosis in Midwestern states independent of the distance they lived from their primary care physician and the socioeconomic status of their residential census tract. Rural women's greater odds of stage IV cancer at diagnosis could affect treatment options and mortality. Further investigation is needed into reasons for these findings.

show abstract

Section: Discussionmentioning

confidence: 99%

Impact of Rurality on Stage IV Ovarian Cancer at Diagnosis: A Midwest Cancer Registry Cohort Study

Weeks

Lynch

West

et al. 2020

The Journal of Rural Health

View full text Add to dashboard Cite

show abstract

“…(28) Interestingly, CRF-driven markers of prolonged sympathetic activity, such as elevated resting heart rate, have been shown to be prognostic for survival in metastatic breast cancer (29) and in ovarian cancer (HR=1.02 for every HR unit increase (CI=1.01-1.04). (30)…”

Section: Discussionmentioning

confidence: 99%

Depression and Oropharynx Cancer Outcome

Shinn¹,

Valentine

Jethanandani

et al. 2016

Psychosomatic Medicine

Self Cite

View full text Add to dashboard Cite

Background Studies have shown a modest relationship between depression and mortality in cancer patients. Our study addressed methodological weaknesses in the literature by restricting the sample to patients with one cancer type, adjusting for factors known to affect outcome, and following patients for a sufficient period of time. Methods We prospectively followed patients newly diagnosed with squamous cell oropharyngeal cancer from the start of radiation therapy until death or until date of last clinical visit. All patients were optimally treated with radiation and sometimes chemotherapy. After adjusting for tumor stage, treatment, comorbidities, smoking, excessive alcohol use, and demographic factors, we assessed the effects of baseline self-reported depression on overall survival and recurrence. Results One hundred thirty participants were followed for a median of 5 years. The average age was 56 years, and 83% were male. Eighteen participants died during the study and 15 experienced disease recurrence. Self-reported depression was associated with decreased overall survival duration (hazard ratio [HR] = 3.6; 95% confidence interval [CI] = 1.2-10.8), and disease recurrence (HR = 3.8; 95% CI = 1.2-12.2) in multivariate analysis. In addition, smoking was associated with disease recurrence. Conclusion Patients with oropharyngeal cancer may benefit from depression screening and evidence-based treatments, if appropriate. Future studies are needed to determine whether depression is an independent prognostic factor of outcome and to elucidate biobehavioral mechanisms involved in patients with oropharyngeal cancer. Precis This prospective study evaluated the impact of self-reported depression on outcomes of patients diagnosed with oropharyngeal cancer and treated with radiation (with or without chemotherapy). After following one hundred thirty participants for a median of 5 years, we found that patients' self-reported depression was associated with decreased overall survival duration and disease recurrence.

show abstract

“…The AYA HOPE index expanded the existing cardiovascular, neurologic, gastrointestinal and renal categories in the Charlson and NCI indices and added mental health and obesity/overweight categories that have not been included in the existing comorbidity indices, but are important to health outcomes and can affect treatment, service needs, and survival for AYA cancer patients. (21–24) For example, the AYA HOPE index captured neurological conditions, such as neuropathy, extremity issues, epilepsy, syncope, and cranial nerve issues that may influence therapy or be associated with needs for health services and quality of life in AYA cancer survivors. Our study is the first, to our knowledge, to examine the association of comorbidities and service needs and found that AYA cancer survivors with comorbidities identified by AYA HOPE index were more likely than those without comorbidities to need mental health and pain management services and AYA survivors with more than 2 comorbidities were more likely than those without comorbidity to have fair/poor general health status.…”

Section: Discussionmentioning

confidence: 99%

Impact of the AYA HOPE Comorbidity Index on Assessing Health Care Service Needs and Health Status among Adolescents and Young Adults with Cancer

Prasad

Landry

et al. 2015

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

Background Existing comorbidity indices were not developed for adolescent and young adults (AYA) 15–39 years of age. The aim of this study was to assess impact of comorbidities on healthcare service needs and health status among AYA cancer survivors using the newly developed AYA HOPE comorbidity index in comparison with the existing indices. Methods Data on comorbid conditions were obtained from medical records and service needs and health status were from a survey of AYA cancer survivors. Prevalence of comorbidities based on the AYA HOPE index. Charlson and NCI indices) were compared. Multivariable logistic regression was employed. Results Of the 485 patients, 14.6% had ≥2 comorbidities based on the AYA HOPE Index. Prevalence of mental illness and obesity/overweight, which were not included in existing indices, were 8.2% and 5.8%, respectively. Prevalence of cardiovascular, endocrine, gastrointestinal and neurologic conditions were higher with the AYA HOPE Index than the other two indices. Forty percent of AYA patients reported service needs, particularly for mental health services (25.2%) and support groups (17.7%). Having ≥2 comorbidities on the AYA index was associated with higher mental health service needs (OR: 2.05; 95% CI 1.10–3.82) adjusting for demographic and clinical factors. Comorbidities were associated with fair/poor self-reported health status. Conclusion The AYA HOPE Index is a more comprehensive comorbidity index for AYA cancer patients than existing indices and the number of comorbidities is associated with service needs and health status. Impact The AYA HOPE index could identify patients’ additional service needs early in therapy.

show abstract

Impact of Cardiovascular Comorbidity on Ovarian Cancer Mortality

Cited by 19 publications

References 37 publications

Impact of Rurality on Stage IV Ovarian Cancer at Diagnosis: A Midwest Cancer Registry Cohort Study

Impact of Rurality on Stage IV Ovarian Cancer at Diagnosis: A Midwest Cancer Registry Cohort Study

Depression and Oropharynx Cancer Outcome

Impact of the AYA HOPE Comorbidity Index on Assessing Health Care Service Needs and Health Status among Adolescents and Young Adults with Cancer

Contact Info

Product

Resources

About